54. The Committee welcomed the proposals which had been prepared in response to the issues raised at its 9th Session on this matter[11]. It noted that the intention of the proposed guidelines was to ensure consumer safety, enhance residue monitoring practices and to assist in trade facilitation. In particular, it noted that the major concern was that of acute toxicological or pharmacological responses to residues at injections sites and that the goal was to ensure that there would be no health risks associated with the presence of elevated residues at injection sites.
55. There was general support for the guidance given in the paper that the calculation of risk from consumption of residues at the injection site should be based on the principles of acute reference dose. However, there were several opinions on practices to be followed when sampling tissues for monitoring purposes. The Committee requested that the paper be reviewed in light of other available information such as the discussion document presented by COMISA and guidelines in the European Union.
56. The Committee invited JECFA to examine the issues raised in the paper and in the present discussion. It also requested that the paper be revised by Australia in the light of this advice and be circulated for comments prior to submission for consideration at its next Session.
